FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Lilly Plans 2018 NDA for Migraine Drug After Trial Results

Eli Lilly says its investigational migraine drug lasmiditan met its primary endpoint in SPARTAN, a second Phase 3 study of the therapy, and a 2018 NDA...

Human Drugs

Orphan Status for Omeros Immunoglobulin A Nephropathy Drug

FDA grants Omeros an orphan drug designation for OMS721 for treating Immunoglobulin A (IgA) nephropathy.

Human Drugs

FDA Warning on Compounded Curcumin

FDA warns healthcare professionals about hypersensitivity reactions related to ImprimisRxs curcumin (a component of the spice turmeric) compounded wit...

Human Drugs

Consent Decree Entered Against Utah Drug Outsourcer

A Utah federal judge enters a consent decree of permanent injunction against Isomeric Pharmacy Solutions (Salt Lake City), co-owners William O. Richar...

Human Drugs

FDA Orphan Status for Vision Loss Gene Therapy

FDA grants Applied Genetic Technologies an orphan drug designation for its unidentified gene therapy product candidate for treating X-linked retinitis...

Medical Devices

FDA Clears Bariatric Surgery Clamp

FDA clears a Standard Bariatrics 510(k) for the Standard Clamp, a disposable laparoscopic surgical clamp that is intended to assist surgeons performin...

FDA General

Why Tobacco Detracts from FDAs Budget Case

Alliance for a Stronger FDA explains how tobacco user fees skew the case for raising taxpayer-funded budget levels for FDAs annual congressional appro...

Human Drugs

Daiichi Sankyo Settling Olmesartan Product Cases

Daiichi Sankyo says that it and Forest are settling claims against them alleging their olmesartan products caused sprue-like enteropathy and other gas...

Federal Register

Guide on Child-Resistant Packaging Statements

Federal Register notice: FDA announces the availability of a draft guidance on Child-Resistant Packaging Statements in Drug Product Labeling.

Federal Register

FDA Withdraws Approval for 4 B. Braun Medical Drugs

Federal Register notice: FDA announces that it is withdrawing approval of three NDAs and one ANDA held by B. Braun Medical.